# MAY 1 2 2005 510(k) SUMMARY

The following 510(k) summary is being submitted as required by 21 CFR 807.92(a):

#### **Submission Information**

Contact:

Seayoung Ahn

7612 Barnum Road, Bethesda, MD 20817

Sponsor:

34-6 Keumam-ri, Seotan-myeon,

Pyeongtaek, Gyeonggi-do, 451-852

Republic of Korea

Date Prepared:

February 21, 2004

### Device Identification

Trade Name:

4CIS® SOLAR Spine System and

4CIS<sup>®</sup> APOLLON Spine System

Common Name:

Pedicle Screw Spinal Fixation System

Classification Name:

Spondylolisthesis Spinal Fixation Device System(MNH)

per 21 CFR § 888.3070,

Spinal Pedicle Screw(MNI) per 21 CFR § 888.3070

### Substantially Equivalent Predicate Legally Marketed Devices

The subject devices, 4CIS<sup>®</sup> SOLAR Spine System and 4CIS<sup>®</sup> APOLLON Spine System, are substantially equivalent in function, design, composition, material and intended used to: Global Spinal Fixation System(K001668) and OPTIMA<sup>TM</sup>, Spinal System(K031585)

### **Device Description**

The 4CIS® SOLAR Spine System and 4CIS® APOLLON Spine System are a top-loading multiple component, posterior spinal fixation system which consists of pedicle screws, rods, nuts, and a transverse (cross) linking mechanism.

The 4CIS® SOLAR Spine System and 4CIS® APOLLON Spine System will allow surgeons to build a spinal implant construct to stabilize and promote spinal fusion. 4CIS® SOLAR Spine System and 4CIS® APOLLON Spine System implant components are supplied non-sterile are single use and are fabricated from titanium alloy (Ti-6Al-4V ELI) that conforms to ASTM F136. Various sizes of these

Solco Biomedical Co.,Ltd

# K050471

implants are available. Specialized instruments are available for the application and removal of the 4CIS<sup>R</sup> SOLAR Spine System and 4CIS<sup>R</sup> APOLLON Spine System.

#### Indications for Use

The 4CIS SOLAR Spine System and 4CIS APOLLON Spine System is a pedicle screw system indicated for the treatment of severe Spondylolisthesis (Grade 3 and 4) of the L5-S1 vertebra in skeletally mature patients receiving fusion by autogenous bon graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion.

In addition, the 4CIS<sup>®</sup> SOLAR Spine System and 4CIS<sup>®</sup> APOLLON Spine System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine: degenerative Spondylolisthesis with objective evidence of neurological impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor and failed previous fusion (pseudarthrosis).

#### Performance Data

Mechanical testing as listed in **APPENDIX 10** that was conducted in accordance with ASTM F1717 demonstrates equivalence to the above predicate devices.





MAY 1 2 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Solco Biomedical c/o Dr. Saeyoung Ahn 7612 Barnum Road Bethesda, Maryland 20817

Re: K050471

Trade/Device Name: 4CIS® SOLAR Spine System and 4CIS® APOLLON Spine System

Regulation Number: 888.3070(b)(1)

Regulation Name: Pedicle Screw Spinal System

Regulatory Class: Class II Product Code: MNH, MNI Dated: February 22, 2005 Received: February 23, 2005

Dear Mr. Ahn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Miriam Provost, Ph.D.

Acting Director

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known):

K050471

Device Name: 4CIS® SOLAR Spine System and 4CIS® APOLLON Spine System

Indications for Use:

The 4CIS® SOLAR Spine System and 4CIS® APOLLON Spine System are a pedicle screw system indicated for the treatment of severe Spondylolisthesis (Grade 3 and 4) of the L5-S1 vertebra in skeletally mature patients receiving fusion by autogenous bone graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion.

In addition, the 4CIS® SOLAR Spine System and 4CIS® APOLLON Spine System are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine: degenerative Spondylolisthesis with objective evidence of neurological impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor and failed previous fusion (pseudarthrosis).

Prescription Use \_\_X\_\_ (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

510(k) Number KOSO471

Solco Biomedical Co.,Ltd